RecruitingPhase not listedNCT04706663
Precision-Based Genomics in Prostate Cancer
Sponsor: National Cancer Institute (NCI)
Seattle, WA · +10 more sites
Prostate Cancer clinical trials in Seattle, WA
48 recruiting prostate cancer studies with a site in Seattle, WA.
RecruitingPhase 1NCT03460977
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Sponsor: Pfizer
Port Angeles, WA · Poulsbo, WA · Seattle, WA · +42 more sites
RecruitingPhase 3NCT06629779
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Sponsor: Pfizer
Bonney Lake, WA · Federal Way, WA · Gig Harbor, WA · +36 more sites
RecruitingPhase 1 / Phase 2NCT07206056
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Sponsor: Novartis Pharmaceuticals
Seattle, WA · +7 more sites
RecruitingPhase 3NCT03678025
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Sponsor: SWOG Cancer Research Network
Bellevue, WA · Kirkland, WA · Seattle, WA · +331 more sites
RecruitingPhase 2NCT07745361
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Sponsor: Monte Rosa Therapeutics, Inc
Seattle, WA · +13 more sites
RecruitingPhase 1NCT05997615
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Sponsor: Astellas Pharma Global Development, Inc.
Seattle, WA · +7 more sites
RecruitingPhase 1 / Phase 2NCT04585750
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Sponsor: PMV Pharmaceuticals, Inc
Seattle, WA · +31 more sites
RecruitingPhase not listedNCT05334069
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Sponsor: Alliance for Clinical Trials in Oncology
Aberdeen, WA · Bellingham, WA · Burien, WA · +744 more sites
RecruitingPhase 2NCT06632977
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Sponsor: Alliance for Clinical Trials in Oncology
Edmonds, WA · Seattle, WA · +106 more sites
RecruitingPhase 3NCT07200830
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Sponsor: Alliance for Clinical Trials in Oncology
Edmonds, WA · Seattle, WA · +136 more sites
RecruitingPhase 2NCT06172478
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Sponsor: Daiichi Sankyo
Seattle, WA · +12 more sites
RecruitingPhase 1NCT06095089
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Sponsor: Janssen Research & Development, LLC
Seattle, WA · +11 more sites
RecruitingPhase 1NCT06801236
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Acerand Therapeutics (Hong Kong) Limited
Seattle, WA · +7 more sites
RecruitingPhase 1NCT07082920
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Sponsor: Janssen Research & Development, LLC
Seattle, WA · +3 more sites
RecruitingPhase 3NCT07164443
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Sponsor: Janssen Research & Development, LLC
Seattle, WA · +51 more sites
RecruitingPhase 3NCT07225946
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Janssen Research & Development, LLC
Seattle, WA · +57 more sites
RecruitingPhase 2 / Phase 3NCT06780670
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Sponsor: Novartis Pharmaceuticals
Seattle, WA · +34 more sites
RecruitingPhase 1NCT07006727
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Sponsor: Novartis Pharmaceuticals
Seattle, WA · +3 more sites
RecruitingPhase 1NCT05983432
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Sponsor: SystImmune Inc.
Seattle, WA · +21 more sites
RecruitingPhase 2NCT04038502
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Sponsor: VA Office of Research and Development
Seattle, WA · +17 more sites
RecruitingPhase 2NCT05011383
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Sponsor: VA Office of Research and Development
Seattle, WA · +16 more sites
RecruitingPhase 1NCT07080242
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Sponsor: SystImmune Inc.
Seattle, WA · +23 more sites
RecruitingPhase not listedNCT04995198
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
Sponsor: Prostate Cancer Clinical Trials Consortium
Seattle, WA · +2 more sites
RecruitingPhase 2NCT06111781
The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
Sponsor: Yale University
Seattle, WA · +3 more sites
RecruitingPhase not listedNCT00756665
Prostate Active Surveillance Study
Sponsor: University of Washington
Seattle, WA · +8 more sites
RecruitingPhase 1NCT04221542
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Amgen
Seattle, WA · +24 more sites
RecruitingPhase 2NCT06844383
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
Sponsor: Prostate Cancer Clinical Trials Consortium
Seattle, WA · +7 more sites
RecruitingPhase 1 / Phase 2NCT04104776
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Sponsor: Novartis Pharmaceuticals
Seattle, WA · +20 more sites
RecruitingPhase 3NCT04423211
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Sponsor: ECOG-ACRIN Cancer Research Group
Aberdeen, WA · Bellingham, WA · Centralia, WA · +338 more sites
RecruitingPhase 2NCT06842498
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sponsor: Kyntra Bio
Seattle, WA · Tacoma, WA · +20 more sites
RecruitingPhase 1 / Phase 2NCT06236139
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Fred Hutchinson Cancer Center
Seattle, WA
RecruitingPhase 1NCT06067841
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Sponsor: Bristol-Myers Squibb
Seattle, WA · +7 more sites
RecruitingPhase not listedNCT01050504
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
Sponsor: University of Washington
Seattle, WA
RecruitingPhase 2NCT06145633
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Sponsor: Fred Hutchinson Cancer Center
Seattle, WA
RecruitingPhase 2NCT04363164
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Seattle, WA · +5 more sites
RecruitingPhase 1 / Phase 2NCT05652686
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Sponsor: Phanes Therapeutics
Seattle, WA · +14 more sites
RecruitingPhase 3NCT06592924
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Sponsor: Canadian Cancer Trials Group
Aberdeen, WA · Bellevue, WA · Bellingham, WA · +371 more sites
RecruitingPhase 1NCT05413421
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Sponsor: ORIC Pharmaceuticals
Seattle, WA · +19 more sites
RecruitingPhase 2NCT05422911
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Sponsor: Sun Pharmaceutical Industries Limited
Seattle, WA · +11 more sites
RecruitingPhase not listedNCT03151629
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Sponsor: Prostate Cancer Clinical Trials Consortium
Seattle, WA · +47 more sites
RecruitingPhase 2NCT04986423
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Sponsor: Zenith Epigenetics
Seattle, WA · +15 more sites
RecruitingPhase 2NCT04606446
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Sponsor: Pfizer
Seattle, WA · +21 more sites
RecruitingPhase 1 / Phase 2NCT06395519
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Sponsor: 858 Therapeutics, Inc.
Seattle, WA · +13 more sites
RecruitingPhase 1NCT06778863
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Sponsor: Clasp Therapeutics, Inc.
Seattle, WA · +20 more sites
RecruitingPhase 2NCT05806515
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Sponsor: SWOG Cancer Research Network
Aberdeen, WA · Bellingham, WA · Bremerton, WA · +130 more sites
RecruitingPhase 1NCT05107674
A Study of NX-1607 in Adults With Advanced Malignancies
Sponsor: Nurix Therapeutics, Inc.
Seattle, WA · +9 more sites
Not yet recruitingPhase 1NCT07803653
IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer
Sponsor: Fred Hutchinson Cancer Center
Seattle, WA
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.